Profarma Distribuidora De Stock Shares Outstanding
PFRM3 Stock | BRL 6.84 0.09 1.33% |
Profarma Distribuidora de fundamentals help investors to digest information that contributes to Profarma Distribuidora's financial success or failures. It also enables traders to predict the movement of Profarma Stock. The fundamental analysis module provides a way to measure Profarma Distribuidora's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Profarma Distribuidora stock.
Profarma |
Profarma Distribuidora de Company Shares Outstanding Analysis
Profarma Distribuidora's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Profarma Distribuidora Shares Outstanding | 122.61 M |
Most of Profarma Distribuidora's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Profarma Distribuidora de is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Profarma Distribuidora de has 122.61 M of shares currently outstending. This is 32.08% lower than that of the Health Care Providers & Services sector and 18.89% lower than that of the Health Care industry. The shares outstanding for all Brazil stocks is 78.56% higher than that of the company.
Profarma Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Profarma Distribuidora's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Profarma Distribuidora could also be used in its relative valuation, which is a method of valuing Profarma Distribuidora by comparing valuation metrics of similar companies.Profarma Distribuidora is currently under evaluation in shares outstanding category among its peers.
Profarma Fundamentals
Return On Equity | 0.0645 | |||
Return On Asset | 0.0368 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.03 % | |||
Current Valuation | 1.35 B | |||
Shares Outstanding | 122.61 M | |||
Shares Owned By Insiders | 66.17 % | |||
Shares Owned By Institutions | 26.52 % | |||
Price To Earning | (6.45) X | |||
Price To Book | 0.35 X | |||
Price To Sales | 0.06 X | |||
Revenue | 6.41 B | |||
Gross Profit | 907.57 M | |||
EBITDA | 225.52 M | |||
Net Income | 78.19 M | |||
Cash And Equivalents | 139.49 M | |||
Cash Per Share | 1.86 X | |||
Total Debt | 740.04 M | |||
Debt To Equity | 91.40 % | |||
Current Ratio | 1.27 X | |||
Book Value Per Share | 8.86 X | |||
Cash Flow From Operations | 107.58 M | |||
Earnings Per Share | 0.71 X | |||
Target Price | 7.5 | |||
Number Of Employees | 7.08 K | |||
Beta | 1.14 | |||
Market Capitalization | 399.71 M | |||
Total Asset | 4.03 B | |||
Retained Earnings | 92 M | |||
Working Capital | 615 M | |||
Current Asset | 1.57 B | |||
Current Liabilities | 951 M | |||
Z Score | 1.0 | |||
Annual Yield | 0.05 % | |||
Five Year Return | 1.29 % | |||
Net Asset | 4.03 B | |||
Last Dividend Paid | 0.27 |
About Profarma Distribuidora Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Profarma Distribuidora de's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Profarma Distribuidora using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Profarma Distribuidora de based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Profarma Stock Analysis
When running Profarma Distribuidora's price analysis, check to measure Profarma Distribuidora's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Profarma Distribuidora is operating at the current time. Most of Profarma Distribuidora's value examination focuses on studying past and present price action to predict the probability of Profarma Distribuidora's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Profarma Distribuidora's price. Additionally, you may evaluate how the addition of Profarma Distribuidora to your portfolios can decrease your overall portfolio volatility.